OPKO Health to Report Fourth Quarter 2021 Financial Results on February 24, 2022GlobeNewsWire • 02/17/22
Pfizer and OPKO's Once-Weekly NGENLA™ (somatrogon) Injection Receives Marketing Authorization in European Union for Treatment of Pediatric Growth Hormone DeficiencyBusiness Wire • 02/15/22
Analysts Estimate OPKO Health (OPK) to Report a Decline in Earnings: What to Look Out forZacks Investment Research • 02/10/22
OPKO Health (OPK) Stock Sinks As Market Gains: What You Should KnowZacks Investment Research • 02/03/22
Pfizer - OPKO Health's Growth Hormone Deficiency Candidate Receives FDA Response LetterBenzinga • 01/24/22
Pfizer and OPKO Provide Update on the Biologics License Application for Somatrogon for Pediatric Growth Hormone DeficiencyBusiness Wire • 01/21/22
OPKO Health to Participate in the 40th Annual J.P. Morgan Healthcare ConferenceBusiness Wire • 01/05/22
OPKO Health Announces Topline Results from Phase 2 Trial Evaluating RAYALDEE to Treat Symptomatic COVID-19 OutpatientsGlobeNewsWire • 12/23/21